Literature DB >> 28123178

Clinical roles of calcium channel blockers in ischemic heart diseases.

Daisuke Sueta1, Noriaki Tabata1, Seiji Hokimoto1.   

Abstract

Calcium (Ca) channel blockers (CCBs) inhibit Ca2+ channels in the myocardium or vascular smooth muscle cells, inhibit myocardium contraction, inhibit the impulse conduction system (anti-arrhythmias) and cause vasodilation. New classifications based on subtypes of Ca channels and α1 subunits have been proposed. Moreover, CCBs have pleiotropic effects on coronary spastic angina (CSA), including variant angina, myocardial infarction (MI) and stent thrombosis (ST). Although the roles of CCBs in clinical situations remain unknown, further studies in this field are expected to broaden our understanding. In this article, we explain the clinical roles of CCBs in ischemic heart diseases, such as CSA, MI and ST, based on previous knowledge and as demonstrated in representative clinical trials.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28123178     DOI： 10.1038/hr.2016.183

Source DB:  PubMed          Journal:  Hypertens Res        ISSN： 0916-9636            Impact factor:   3.872


  90 in total

1.  Clinical outcomes of percutaneous coronary intervention for acute coronary syndrome between hospitals with and without onsite cardiac surgery backup.

Authors:  Tomonori Akasaka; Seiji Hokimoto; Daisuke Sueta; Noriaki Tabata; Shuichi Oshima; Koichi Nakao; Kazuteru Fujimoto; Yuji Miyao; Hideki Shimomura; Ryusuke Tsunoda; Toyoki Hirose; Ichiro Kajiwara; Toshiyuki Matsumura; Natsuki Nakamura; Nobuyasu Yamamoto; Shunichi Koide; Shinichi Nakamura; Yasuhiro Morikami; Naritsugu Sakaino; Koichi Kaikita; Sunao Nakamura; Kunihiko Matsui; Hisao Ogawa
Journal:  J Cardiol       Date:  2016-02-23       Impact factor: 3.159

2.  Short-acting nifedipine and diltiazem do not reduce the incidence of cardiac events in patients with healed myocardial infarction. Secondary Prevention Group.

Authors:  K Ishikawa; S Nakai; T Takenaka; K Kanamasa; J Hama; I Ogawa; T Yamamoto; M Oyaizu; A Kimura; K Yamamoto; H Yabushita; R Katori
Journal:  Circulation       Date:  1997-05-20       Impact factor: 29.690

3.  Clinical outcomes following coronary stenting in Japanese patients treated with and without proton pump inhibitor.

Authors:  Tadasuke Chitose; Seiji Hokimoto; Shuichi Oshima; Koichi Nakao; Kazuteru Fujimoto; Yuji Miyao; Hideki Shimomura; Ryusuke Tsunoda; Hideki Maruyama; Toyoki Hirose; Koichiro Yamamoto; Michio Mizobe; Koichi Kaikita; Sunao Nakamura; Hisao Ogawa
Journal:  Circ J       Date:  2011-12-01       Impact factor: 2.993

4.  Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial.

Authors:  Henry R Black; William J Elliott; Gregory Grandits; Patricia Grambsch; Tracy Lucente; William B White; James D Neaton; Richard H Grimm; Lennart Hansson; Yves Lacourciere; James Muller; Peter Sleight; Michael A Weber; Gordon Williams; Janet Wittes; Alberto Zanchetti; Robert J Anders
Journal:  JAMA       Date:  2003 Apr 23-30       Impact factor: 56.272

5.  Hypotensive action and increased plasma renin activity by Ca2+ antagonist (Nifedipine) in hypertensive patients.

Authors:  K Aoki; T Yoshida; S Kato; K Tazumi; I Sato
Journal:  Jpn Heart J       Date:  1976-07

6.  Verapamil for unstable angina at rest: a short-term randomized, double-blind study.

Authors:  D R Mauritson; S M Johnson; M D Winniford; J R Cary; J T Willerson; L D Hillis
Journal:  Am Heart J       Date:  1983-10       Impact factor: 4.749

7.  Impact of coronary artery stents on mortality and nonfatal myocardial infarction: meta-analysis of randomized trials comparing a strategy of routine stenting with that of balloon angioplasty.

Authors:  Jassim Al Suwaidi; David R Holmes; Amar M Salam; Ryan Lennon; Peter B Berger
Journal:  Am Heart J       Date:  2004-05       Impact factor: 4.749

8.  Antihypertensive effect of (4-2'-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarbonic acid dimethylester (Nifedipine, Bay-a 1040), a new coronary dilator.

Authors:  M Murakami; E Murakami; N Takekoshi; M Tsuchiya; T Kin
Journal:  Jpn Heart J       Date:  1972-03

9.  Comparative effects of valsartan in combination with cilnidipine or amlodipine on cardiac remodeling and diastolic dysfunction in Dahl salt-sensitive rats.

Authors:  Kai Nagasawa; Keiji Takahashi; Natsumi Matsuura; Miwa Takatsu; Takuya Hattori; Shogo Watanabe; Eri Harada; Kazumi Niinuma; Toyoaki Murohara; Kohzo Nagata
Journal:  Hypertens Res       Date:  2014-09-11       Impact factor: 3.872

10.  The risk of myocardial infarction associated with antihypertensive drug therapies.

Authors:  B M Psaty; S R Heckbert; T D Koepsell; D S Siscovick; T E Raghunathan; N S Weiss; F R Rosendaal; R N Lemaitre; N L Smith; P W Wahl
Journal:  JAMA       Date:  1995 Aug 23-30       Impact factor: 56.272
View more
  3 in total

Review 1.  Partners in Crime: Towards New Ways of Targeting Calcium Channels.

Authors:  Lucile Noyer; Loic Lemonnier; Pascal Mariot; Dimitra Gkika
Journal:  Int J Mol Sci       Date:  2019-12-16       Impact factor: 5.923

2.  Granule of BU-XIN RUAN-MAI Attenuates the Patients' Angina Pectoris of Coronary Heart Disease via Regulating miR-542-3p/GABARAP Signaling.

Authors:  Dong Yan; Li-Li Zhao; Bo-Wen Yue; Hui Qian; Zi-Han Zhang; Ning Wang; Shi-Hai Yan; Yu-Liang Qian
Journal:  Evid Based Complement Alternat Med       Date:  2019-12-26       Impact factor: 2.629

3.  Acute vaping exacerbates microbial pneumonia due to calcium (Ca2+) dysregulation.

Authors:  Rui Zhang; Myles M Jones; De'Jana Parker; Ronna E Dornsife; Nathan Wymer; Rob U Onyenwoke; Vijay Sivaraman
Journal:  PLoS One       Date:  2021-08-12       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.